GlassScriptPhysician profile
Kevin Mcelligott
NPI 1447694864
$1,011.18
in general payments reported to CMS, 2019-2025
19 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.00 · 2021: $50.27 · 2023: $146 · 2024: $360 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $160.13 | 2020-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $150.31 | 2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $130.60 | 2023-2025 | |
| Abbott Laboratories | $116.19 | 2024-2025 | Cardiomems |
| Janssen Pharmaceuticals, INC | $100.72 | 2020-2024 | Xarelto |
| Novo Nordisk INC | $52.25 | 2024-2025 | Wegovy, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.89 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $34.07 | 2023-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $33.76 | 2021-2025 | Camzyos |
| Abiomed | $31.62 | 2024 | Impella |
| Atricure, INC. | $23.64 | 2025 | Atriclip Laa Exclusion System |
| Medtronic, INC. | $21.36 | 2024 | Ffrangio |
| Azurity Pharmaceuticals, INC. | $18.00 | 2024 | Edarbyclor |
| Sanofi-Aventis U.S. LLC | $17.32 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.12 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $15.82 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.78 | 2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2025 | |
| Cvrx, INC. | $9.70 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Mcelligott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.